HOME >> MEDICINE >> NEWS
Drug to block mother-to-child HIV transmission induces resistance more often than previously thought

The incidence of drug resistance associated with single-dose nevirapine, a drug used to prevent mother-to-child transmission of HIV-1, may be substantially higher than previously thought and of particular risk for those infected with HIV-1 subtype C, according to three new studies published in the July 1 issue of The Journal of Infectious Diseases, now available online.

A single dose of nevirapine given to an HIV-infected pregnant woman during delivery, and another given to her newborn, can cut the rate of mother-to-child HIV transmission in half. The relative simplicity and affordability of single-dose nevirapine have made it the drug of choice for prevention of mother-to-child transmission in many developing countries.

This new research expands understanding of the risks of drug resistance associated with single-dose nevirapine, but as noted by all three research groups, the clinical implications for patients are not yet clear. More research will be needed to determine whether nevirapine used to prevent mother-to-child transmission affects the chances of successful treatment later with nonnucleoside reverse transcriptase inhibitors, the class of drug to which nevirapine belongs.

Two of the studies analyzed the incidence of nevirapine-associated resistance using laboratory tests more sensitive than standard genotypic assays. In the first, researchers led by Jeffrey A. Johnson, PhD, of the Centers for Disease Control and Prevention, used a new, very sensitive technique to detect resistance mutations in samples of HIV-1 obtained from 50 South African women before and after treatment with single-dose nevirapine. Using a less-sensitive conventional technique called sequence analysis, researchers had previously estimated that viral resistance to nevirapine emerged in approximately 40 percent of women after receiving the single-dose therapy. In contrast, Dr. Johnson and colleagues concluded that resistance emerges in at least 65 percent of women a
'"/>

Contact: Steve Baragona
sbaragona@idsociety.org
703-299-0412
Infectious Diseases Society of America
1-Jun-2005


Page: 1 2 3

Related medicine news :

1. Scientists train nano-building blocks to take on new shapes, as reported in Science
2. Future therapies for stroke may block cell death
3. Scavenger cells may have role blocking obesity, Stanford study shows
4. Computer scientist reveals the math and science behind blockbuster movies
5. First-degree fetal heart block may be reversible
6. MR angiography highly accurate in detecting blocked arteries
7. Scientists stop colon cancer growth in mice by blocking just one enzyme
8. A world first in the treatment of a young patient with a completely blocked yet vital heart artery
9. People often forgo using lifesaving beta blockers despite health insurance
10. Drug could change the standard treatment during procedures to clear blocked arteries
11. Tumor necrosis factor blockers may not cause cancer after all

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... The National Business Research ... National Registry of Emergency Medical Technicians and welcomes this organization to the ... Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award ...
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist Dr. John ... have never imagined back in 1991 that this journey would have taken me into ... last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more ... CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a more ... with fewer resources. It highlights the business’ principles, research and collaboration efforts in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, ... the first in a new class of photodynamic cosmetics (PDC). , Allumera® is ... visibly reduce outward signs of aging, and minimize the appearance of pores – ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... VANCOUVER , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) ... the Bloom Burton & Co. Healthcare Investor Conference 2017 at the ... Edward Wright , Chief Executive Officer of the Company is ... Company,s CFO, Richard Bear and the Chairman of the ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
Breaking Medicine Technology:
Cached News: